Sales and marketing expenses were $6.7 million for Q1 2020, compared to $3.8 million for the same period in 2025, an increase of $2.9 million or 75%. This increase was due primarily to additional personal cost of $1.9 million and increase in travel costs of $0.5 million, resulting from the expansion of our clinical and sales teams due to the IRIS integration, as well as additional amortization expense of acquired intangible assets of $0.2 million.

May 13, 2026 / CFO / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2026-05-13 | transcript 5642d319-240a-4ff9-b82b-cb3616ca9dcf | chars 6746-7197 | segment 6

This increase was due to higher personal costs, including share-based compensation expense of $1.4 million, resulting from increases in headcount in our clinical team, as well as increased costs of $0.9 million due to the consolidation of ERAS, partial offset by decreased marketing costs of $0.2 million and decreased travel costs of $0.2 million.

Mar 17, 2026 / CFO / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2026-03-17 | transcript 8f491f99-4fcf-4e44-8e55-772f0b8c7b6d | chars 9062-9410 | segment 8

Additionally, our travel costs and marketing activities increased 0.1 million each in the quarter, General administrative expenses were $3 million in Q2 compared to $2 million for the same period in 2021, an increase of $1 million, or 51%.

Aug 9, 2022 / CFO / receipt, needs a key / Danilo D'Alessandro, CFO | earnings call 2022-08-09 | transcript 0aa7b8e1-994c-41e5-be18-e767c02d828f | chars 5592-5831 | segment 5